Nothing Special   »   [go: up one dir, main page]

BR112014028130A2 - Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos - Google Patents

Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos

Info

Publication number
BR112014028130A2
BR112014028130A2 BR112014028130A BR112014028130A BR112014028130A2 BR 112014028130 A2 BR112014028130 A2 BR 112014028130A2 BR 112014028130 A BR112014028130 A BR 112014028130A BR 112014028130 A BR112014028130 A BR 112014028130A BR 112014028130 A2 BR112014028130 A2 BR 112014028130A2
Authority
BR
Brazil
Prior art keywords
hydrochloride salt
pharmaceutical composition
peptide
preventing
cat allergy
Prior art date
Application number
BR112014028130A
Other languages
English (en)
Inventor
Laidler Paul
Farkas Imre
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of BR112014028130A2 publication Critical patent/BR112014028130A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

SAL DE CLORIDRATO DE UM PEPTÍDEO, COMPOSIÇÃO FARMACÊUTICA, USO DE UM SAL DE CLORIDRATO, USO DE UMA COMPOSIÇÃO FARMACÊUTICA, E, MÉTODO PARA EVITAR OU TRATAR ALERGIA A GATOS. A presente invenção refere-se a um sal de cloridrato de um peptídeo consistindo da sequência de CPAVKRDVDLFLT (SEQ ID NO: 1), assim como suas combinações com outros peptídeos para fins imunossupressores.
BR112014028130A 2012-05-11 2013-05-09 Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos BR112014028130A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201208293A GB201208293D0 (en) 2012-05-11 2012-05-11 Hydrochlorice salt of peptide
PCT/GB2013/051201 WO2013167897A1 (en) 2012-05-11 2013-05-09 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy

Publications (1)

Publication Number Publication Date
BR112014028130A2 true BR112014028130A2 (pt) 2017-08-15

Family

ID=46396890

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014028130A BR112014028130A2 (pt) 2012-05-11 2013-05-09 Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos

Country Status (17)

Country Link
US (1) US9657061B2 (pt)
EP (1) EP2847209B8 (pt)
JP (1) JP5982562B2 (pt)
KR (1) KR20150014955A (pt)
CN (1) CN104428311B (pt)
AU (1) AU2013257784A1 (pt)
BR (1) BR112014028130A2 (pt)
CA (1) CA2873120A1 (pt)
EA (1) EA201492068A1 (pt)
GB (2) GB201208293D0 (pt)
HK (1) HK1201850A1 (pt)
IL (1) IL235388A (pt)
IN (1) IN2014DN09367A (pt)
MX (1) MX2014013394A (pt)
SG (1) SG11201407446TA (pt)
WO (1) WO2013167897A1 (pt)
ZA (1) ZA201408290B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
SI3626731T1 (sl) 2014-12-23 2021-12-31 Immatics Biotechnologies Gmbh Novi peptidi in kombinacija peptidov za uporabo v imunoterapiji proti hepatocelularnem karcinomu (HCC) in drugim oblikam raka
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
ES2981540T3 (es) 2015-03-27 2024-10-09 Immatics Biotechnologies Gmbh Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores (SEQ ID 274 - IGF-004)
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
TWI792442B (zh) * 2021-07-23 2023-02-11 建誼生技股份有限公司 依特卡肽鹽酸鹽之製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1453539B1 (en) 2001-12-05 2008-11-19 Circassia Limited Immunotherapeutic methods and systems
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
US8652485B2 (en) * 2007-08-15 2014-02-18 Circassia Limited Peptide for vaccine
GB2455108A (en) * 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
ES2617921T3 (es) * 2010-03-31 2017-06-20 Stabilitech Ltd. Excipientes para estabilizar partículas virales

Also Published As

Publication number Publication date
KR20150014955A (ko) 2015-02-09
JP2015517484A (ja) 2015-06-22
CA2873120A1 (en) 2013-11-14
HK1201850A1 (en) 2015-09-11
US9657061B2 (en) 2017-05-23
EP2847209B8 (en) 2020-10-07
CN104428311B (zh) 2019-11-01
JP5982562B2 (ja) 2016-08-31
CN104428311A (zh) 2015-03-18
US20150110820A1 (en) 2015-04-23
ZA201408290B (en) 2016-01-27
GB201208293D0 (en) 2012-06-20
GB2517354A (en) 2015-02-18
EP2847209B1 (en) 2020-08-05
IN2014DN09367A (pt) 2015-07-17
IL235388A (en) 2016-06-30
GB201421491D0 (en) 2015-01-14
EP2847209A1 (en) 2015-03-18
EA201492068A1 (ru) 2015-03-31
WO2013167897A1 (en) 2013-11-14
AU2013257784A1 (en) 2014-11-20
SG11201407446TA (en) 2015-03-30
MX2014013394A (es) 2015-02-04

Similar Documents

Publication Publication Date Title
UA118167C2 (uk) Пептид та його застосування
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
BR112014000466A2 (pt) polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos
CO2017005995A2 (es) Composiciones para el cuidado bucal y métodos de uso
CL2014001994A1 (es) Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
EA201790378A1 (ru) Заключенное в липосому аффинное лекарственное средство
EA201490809A1 (ru) Способы и композиции для лечения неэффективного эритропоэза
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
MX2013013913A (es) Polipeptidos.
CO2017009433A2 (es) Proteínas específicas para pioverdina y pioquelina
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
EP4414376A3 (en) Novel depsipeptide and uses thereof
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
BR112013003722A2 (pt) produtos para cuidado e métodos de uso e fabricação dos mesmos
BR112014025041B8 (pt) Composição farmacêutica
BR112016000565A2 (pt) polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma
BR112015001096A2 (pt) derivados de di e tri-heteroaril como inibidores de agregação de proteína
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]